ICS-formoterol reliever versus ICS and short-acting β(2)-agonist reliever in asthma: a systematic review and meta-analysis

BACKGROUND: The Global Initiative for Asthma recommends as-needed inhaled corticosteroid (ICS)-formoterol as an alternative to maintenance ICS plus short-acting β(2)-agonist (SABA) reliever at step 2 of its stepwise treatment algorithm. Our aim was to assess the efficacy and safety of these two trea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ERJ Open Res
Hlavní autoři: Hatter, Lee, Bruce, Pepa, Braithwaite, Irene, Holliday, Mark, Fingleton, James, Weatherall, Mark, Beasley, Richard
Médium: Artigo
Jazyk:Inglês
Vydáno: European Respiratory Society 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7836558/
https://ncbi.nlm.nih.gov/pubmed/33532465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00701-2020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky